Physician profile
Timothy P Powers
NPI 1861486573
$1,625.86
in general payments reported to CMS, 2019-2025
17 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.66 · 2020: $61.60 · 2021: $102 · 2022: $369 · 2023: $292 · 2024: $222 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.25 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $219.19 | 2023-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $193.60 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Biotissue Holdings INC. | $186.04 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.28 | 2019-2021 | |
| Astellas Pharma Global Development | $92.08 | 2025 | Izervay |
| Eyepoint US, INC. | $82.95 | 2022 | |
| Genentech, INC. | $79.92 | 2023 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $79.12 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $58.35 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $55.77 | 2023-2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $48.12 | 2024-2025 | Acthar |
| Allergan, INC. | $45.54 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $38.38 | 2022-2023 | Vyzulta |
| Horizon Therapeutics Plc | $36.14 | 2021-2023 | Tepezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $14.50 | 2021 | |
| Dompe US, INC. | $13.63 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.